The Caris Lookback Program flagged 13,293 patients as potentially eligible for newly approved targeted therapies across 10 tumor types
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new Caris-led publication in The Oncologist. Notably, the study demonstrates how the Caris Lookback Program proactively identifies previously-profiled patients who become eligible for newly approved targeted therapies.
A Dynamic Solution to Static Reporting
Most labs generate molecular profiling reports that capture clinical knowledge only at a single moment in time. However, as new biomarker–drug associations and therapeutic indications continue to emerge, patients with previously identified biomarkers can miss out on newly approved treatment opportunities. Meanwhile, clinicians increasingly struggle to keep pace with rapidly evolving evidence.
Since 2014, Caris has tackled this challenge head-on through its dynamic Caris Lookback Program. Specifically, Caris continuously monitors new FDA approvals and guideline updates tied to biomarker-linked therapies. Whenever the team identifies new clinical actionability, Caris retrospectively reviews prior patient test results to pinpoint those whose molecular profiles align with the new or updated recommendations — all without requiring additional testing. Subsequently, coordinated Medical Affairs and Molecular Science Liaison (MSL) outreach proactively alerts treating oncologists. As a result, patients continue to benefit long after their initial testing, while oncologists gain timely access to updated therapeutic insights.
“As the number of biomarker-driven therapies continues to accelerate, a static analysis limited to a single moment-in-time is no longer sufficient in many cases,” said James Hamrick, MD, MPH, Chairman, Caris Precision Oncology Alliance. “The Caris Lookback Program was designed to extend the clinical value of comprehensive molecular profiling over time by continuously reviewing prior results through the lens of newly emerging therapeutic evidence, helping ensure that patients and their physicians can benefit from ongoing advances in precision oncology.”
Study Findings Reveal Broad Clinical Impact
In this large real-world analysis, Caris evaluated 87 biomarker-directed FDA approvals issued between 2018 and 2025 using a structured clinical impact framework. Approximately one-third of these approvals met the criteria for inclusion in the Caris Lookback Program based on their potential clinical value and actionability. Furthermore, drawing from a database of more than 483,000 molecular profiles, the program flagged 13,293 patients as potentially eligible for newly approved targeted therapies across 10 tumor types and multiple tumor-agnostic indications.
The program’s reach extended across a wide range of solid tumors, including non-small cell lung, breast, colorectal, and pancreatic cancers. In particular, non-small cell lung cancer accounted for approximately 40% of the identified opportunities. Additionally, the study highlighted the critical importance of multi-modal profiling, since biomarker detection required diverse methodologies — including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), Immunohistochemistry (IHC), and combinations of these approaches.
Beyond molecular identification, the findings also showcase the effectiveness of proactive clinical engagement. By combining comprehensive molecular profiling with continuous evidence surveillance and targeted physician outreach, the Caris Lookback Program proves how a single comprehensive test can deliver dynamic, longitudinal clinical utility — ultimately helping identify patients who may benefit from newly approved therapies without repeat biopsies or additional testing.
About MI Cancer Seek®
MI Cancer Seek® stands as the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Moreover, MI Cancer Seek is available for both adult and pediatric patients (ages 1+).
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer that actively develops and commercializes innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome, and Whole Transcriptome Sequencing) combined with advanced AI and machine learning, Caris has built the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. By converging next-generation sequencing, AI and machine learning technologies, and high-performance computing, Caris delivers a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions — spanning early detection, diagnosis, monitoring, therapy selection, and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris also operates offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland. Today, Caris and its distributor partners deliver services across the U.S. and other international markets. For more investor relations information on Caris Life Sciences® please visit www.investor.carllifesciences.com.
The post Caris Life Sciences Publishes Study Showing Caris Lookback Program Delivers Ongoing Clinical Value Through Comprehensive Testing with Caris MI Cancer Seek appeared first on PRISM MarketView.